CRDF

Cardiff Oncology Inc. (CRDF) | Rumor.io

Cardiff Oncology

CRDF

Attention (50-day avg)0%

Attention rank (50-day avg)#892

Bullish sentiment (50-day avg)81%

Price to earnings ratio-1.74

Market capitalization93.4M

Earnings per share-0.6

Dividend yield (TTM)—

Revenue (annual)593K

Net income (annual)-45.9M

Social

What share of all stock conversation is about CRDF?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% +0	0% +0	0% -0.01

Sep 29

The market's response to Cardiff Oncology, Inc. (CRDF) has been to push for stronger data, a registrational path, and the resolution of litigation before considering a Phase 3 trial.
Analysts are discussing RAS and CRC, but not onvansertib, a key asset of CRDF, which may indicate a lack of understanding or interest in the company's technology.
The float for CRDF is relatively small at 73 million shares, and there are efforts to encourage large investors or billionaires to buy up a significant portion of the float at the market open.

Generated by AI

Sentiment

Of the messages about CRDF that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% +20	87.88% +4.83	86.17% +12.91	81.35% -0.21
Bearish	0% -20	12.12% -4.83	13.83% -12.91	18.65% +0.21

Bullish· Sep 15

$CRDF is poised for a phase 3 trial with its onvansertib asset, which has a $10B addressable market in the US alone, making it one of the most valuable oncology drugs in development.
A partnership agreement has been reached, clearing onvansertib rights and paving the way for a massive gap up, potentially leading to a real short squeeze.
The stock has significant rerating potential, with some analysts already upgrading their targets, and the market is slowly waking up to the value of this asset, which is already showing signs of a short squeeze with a 30% increase in the week.

Bearish· Jul 15

The company's recent $10 million raise has led to a $30 million decrease in market cap, indicating a possible lack of investor confidence.
The management's decision to sell shares at a low price has been criticized, with some accusing them of being desperate and prioritizing their own interests over the company's.
The company's inability to make progress and its focus on survival rather than value creation have led to a significant decline in stock value, with some analysts slashing their targets from $10 to $2.

Generated by AI

Topics

Of the messages about CRDF that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	27.27%	74.8%	66.19%
Controversies	0%	0%	15.35%	5.8%
Technical Analysis	100%	72.73%	3.94%	14.28%
Analysts	0%	0%	5.91%	8.28%
Earnings	0%	0%	0%	0.89%
Macro	0%	0%	0%	4.56%

Announcements· Sep 14

Cardiff Oncology and Nerviano Medical Sciences have settled their dispute and amended their 2017 Exclusive License Agreement, resolving all outstanding issues related to onvansertib, Cardiff's lead PLK1 inhibitor drug candidate.
The amended agreement strengthens Cardiff's long-term rights to onvansertib, a promising treatment for cancer, beginning with first-line RAS-mutated metastatic colorectal cancer, and establishes an expanded collaborative framework to support onvansertib's continued clinical development.
Cardiff and Nerviano have agreed to a full and mutual release of all claims asserted in the litigation, and plan to jointly request dismissal of all claims with prejudice, with the parties looking forward to working together to advance onvansertib into a global Phase 3 study.

Technical Analysis· Sep 9

$CRDF's MACD is curling back around, indicating a potential reversal.
The stock's RSI is oversold, with a reading of 22, suggesting a possible buying opportunity.
$CRDF's 10-day Moving Average broke above its 50-day Moving Average on August 30, 2021, a bullish indicator.

Generated by AI

Community

Of the messages about CRDF, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	86.05%	80.82%	82.31%
Newcomers	0%	13.95%	19.18%	17.69%

Regulars· Sep 29

The company's management is being criticized for not providing a clear picture of the current situation, which is causing some shareholders to question their decision to vote in favor of a proposed dilution.
Regulars are pointing out a pattern in the market's response to Cardiff Oncology's progress, where each milestone reduces uncertainty but the valuation often acts as if the prior milestones never happened, leading to a pushback of value recognition into the future.
There is concern among regulars that the company may not have enough funds to cover the costs of Phase 3 trials and operations, with estimates suggesting a need for $200-300 million, and that the lack of news from the company is not helping to move the share price up.

Newcomers· Sep 15

New investors are excited about the potential for a short squeeze, with some predicting a price increase to $5+ or even $9+.
The upgrade to Buy from HC Wainwright with a price target of $9 has contributed to the stock's recent surge, with some users attributing the move to the upgrade.
The stock's strong performance, with a 73% increase in a month and a half, has caught the attention of new investors, with some expressing excitement about the potential for further gains.

Generated by AI

News

Cardiff Oncology at H.C. Wainwright conference: trial path clears

15d agoInvesting.com

Cardiff Oncology settles dispute with NMS over onvansertib rights

15d agoInvesting.com

Cardiff Oncology and Nerviano Medical Sciences Amend their 2017 Exclusive License Agreement

Under the terms of the Amendment, all disputed issues are resolvedSAN DIEGO and NERVIANO, Italy, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ: CRDF) ("Cardiff") and Nerviano Medical Sciences S.r.l. ("NMS") today announced that they have reached a settlement and amended their 2017 Exclusive License Agreement, resolving all outstanding disputes between the two companies related to the global rights for onvansertib, Cardiff's lead PLK1 inhibitor drug candidate, and establishing

15d agoYahoo Finance

Cardiff Oncology, Inc. (CRDF) Presents at 8th Annual RAS-Targeted Drug Development Summit - Slideshow (NASDAQ:CRDF) 2026-09-10

2026-09-10. The following slide deck was published by Cardiff Oncology, Inc.

19d agoSeeking Alpha

Cardiff Oncology, Inc. (CRDF) Presents at 8th Annual RAS-Targeted Drug Development Summit - Slideshow

19d agoSeeking Alpha

Cardiff Oncology to Participate in September 2026 Conferences

SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that Mani Mohindru, Ph.D. will participate in two upcoming conferences. Details of the company’s participation are as follows: 8th Annual RAS-Targeted Drug Development Summit Advancing PLK1 Targeted Therapy to Transform Outcomes in RAS Mutant Metastatic Colorectal Cancer; Tuesda

28d agoYahoo Finance

Also Discussed

Investors talking about CRDF also mention

#	Name	Attention
1	Bio-Path Holdings Inc.BPTH	0%0
2	ONCT - Oncternal Therapeutics, Inc.	——
3	ABIO - ARCA biopharma, Inc.	——
4	SEEL - Seelos Therapeutics, Inc.	——
5	Invesco High Income Trust IIVLT	0%0
6	Akari Therapeutics Plc ADRAKTX	0%0
7	Arcadia Biosciences Inc.RKDA	0.01%0
8	Fuwei Films Holdings Co LtdFFHL	0%new
9	Biodexa Pharmaceuticals plc ADRBDRX	0%+0
10	vTv Therapeutics Inc. Class A Common StockVTVT	0%new

Cardiff Oncology Inc.

Healthcare
Biotechnology

Cardiff Oncology Inc. is a clinical-stage biotechnology company focused on developing cancer therapies that target Polo-like Kinase 1 (PLK1), a validated oncology pathway involved in cell division. Its lead product candidate, onvansertib, is an oral and selective PLK1 inhibitor being studied in combination with standard-of-care treatments across multiple cancer types. The company’s current clinical programs center on difficult-to-treat solid tumors and hematologic malignancies, including colorectal cancer, prostate cancer, pancreatic cancer, lung cancer, and breast cancer. Cardiff Oncology’s work is aimed at addressing treatment resistance and improving the effectiveness of existing cancer regimens through combination approaches. Headquartered in San Diego, California, Cardiff Oncology operates as a focused oncology drug development company within the broader biotechnology sector.

Website

Location

11055 Flintkote Avenue

San Diego, CA, 92121

United States

Social

What share of all stock conversation is about CRDF?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% +0	0% +0	0% -0.01

Sep 29

The market's response to Cardiff Oncology, Inc. (CRDF) has been to push for stronger data, a registrational path, and the resolution of litigation before considering a Phase 3 trial.
Analysts are discussing RAS and CRC, but not onvansertib, a key asset of CRDF, which may indicate a lack of understanding or interest in the company's technology.
The float for CRDF is relatively small at 73 million shares, and there are efforts to encourage large investors or billionaires to buy up a significant portion of the float at the market open.

Generated by AI

Sentiment

Of the messages about CRDF that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% +20	87.88% +4.83	86.17% +12.91	81.35% -0.21
Bearish	0% -20	12.12% -4.83	13.83% -12.91	18.65% +0.21

Bullish· Sep 15

$CRDF is poised for a phase 3 trial with its onvansertib asset, which has a $10B addressable market in the US alone, making it one of the most valuable oncology drugs in development.
A partnership agreement has been reached, clearing onvansertib rights and paving the way for a massive gap up, potentially leading to a real short squeeze.
The stock has significant rerating potential, with some analysts already upgrading their targets, and the market is slowly waking up to the value of this asset, which is already showing signs of a short squeeze with a 30% increase in the week.

Bearish· Jul 15

The company's recent $10 million raise has led to a $30 million decrease in market cap, indicating a possible lack of investor confidence.
The management's decision to sell shares at a low price has been criticized, with some accusing them of being desperate and prioritizing their own interests over the company's.
The company's inability to make progress and its focus on survival rather than value creation have led to a significant decline in stock value, with some analysts slashing their targets from $10 to $2.

Generated by AI

Topics

Of the messages about CRDF that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	27.27%	74.8%	66.19%
Controversies	0%	0%	15.35%	5.8%
Technical Analysis	100%	72.73%	3.94%	14.28%
Analysts	0%	0%	5.91%	8.28%
Earnings	0%	0%	0%	0.89%
Macro	0%	0%	0%	4.56%

Announcements· Sep 14

Cardiff Oncology and Nerviano Medical Sciences have settled their dispute and amended their 2017 Exclusive License Agreement, resolving all outstanding issues related to onvansertib, Cardiff's lead PLK1 inhibitor drug candidate.
The amended agreement strengthens Cardiff's long-term rights to onvansertib, a promising treatment for cancer, beginning with first-line RAS-mutated metastatic colorectal cancer, and establishes an expanded collaborative framework to support onvansertib's continued clinical development.
Cardiff and Nerviano have agreed to a full and mutual release of all claims asserted in the litigation, and plan to jointly request dismissal of all claims with prejudice, with the parties looking forward to working together to advance onvansertib into a global Phase 3 study.

Technical Analysis· Sep 9

$CRDF's MACD is curling back around, indicating a potential reversal.
The stock's RSI is oversold, with a reading of 22, suggesting a possible buying opportunity.
$CRDF's 10-day Moving Average broke above its 50-day Moving Average on August 30, 2021, a bullish indicator.

Generated by AI

Community

Of the messages about CRDF, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	86.05%	80.82%	82.31%
Newcomers	0%	13.95%	19.18%	17.69%

Regulars· Sep 29

The company's management is being criticized for not providing a clear picture of the current situation, which is causing some shareholders to question their decision to vote in favor of a proposed dilution.
Regulars are pointing out a pattern in the market's response to Cardiff Oncology's progress, where each milestone reduces uncertainty but the valuation often acts as if the prior milestones never happened, leading to a pushback of value recognition into the future.
There is concern among regulars that the company may not have enough funds to cover the costs of Phase 3 trials and operations, with estimates suggesting a need for $200-300 million, and that the lack of news from the company is not helping to move the share price up.

Newcomers· Sep 15

New investors are excited about the potential for a short squeeze, with some predicting a price increase to $5+ or even $9+.
The upgrade to Buy from HC Wainwright with a price target of $9 has contributed to the stock's recent surge, with some users attributing the move to the upgrade.
The stock's strong performance, with a 73% increase in a month and a half, has caught the attention of new investors, with some expressing excitement about the potential for further gains.

Generated by AI

Cardiff Oncology

Social

Sep 29

Bullish· Sep 15

Bearish· Jul 15

Announcements· Sep 14

Technical Analysis· Sep 9

Regulars· Sep 29

Newcomers· Sep 15

Cardiff Oncology at H.C. Wainwright conference: trial path clears

Cardiff Oncology settles dispute with NMS over onvansertib rights

Cardiff Oncology and Nerviano Medical Sciences Amend their 2017 Exclusive License Agreement

Cardiff Oncology, Inc. (CRDF) Presents at 8th Annual RAS-Targeted Drug Development Summit - Slideshow (NASDAQ:CRDF) 2026-09-10

Cardiff Oncology, Inc. (CRDF) Presents at 8th Annual RAS-Targeted Drug Development Summit - Slideshow

Cardiff Oncology to Participate in September 2026 Conferences

Also Discussed

Cardiff Oncology Inc.

Company Information

Location

Cardiff Oncology at H.C. Wainwright conference: trial path clears

Cardiff Oncology settles dispute with NMS over onvansertib rights

Cardiff Oncology and Nerviano Medical Sciences Amend their 2017 Exclusive License Agreement

Cardiff Oncology, Inc. (CRDF) Presents at 8th Annual RAS-Targeted Drug Development Summit - Slideshow (NASDAQ:CRDF) 2026-09-10

Cardiff Oncology, Inc. (CRDF) Presents at 8th Annual RAS-Targeted Drug Development Summit - Slideshow

Cardiff Oncology to Participate in September 2026 Conferences

Also Discussed

Social

Sep 29

Bullish· Sep 15

Bearish· Jul 15

Announcements· Sep 14

Technical Analysis· Sep 9

Regulars· Sep 29

Newcomers· Sep 15